Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil

Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil

Abstract INTRODUCTION: Benznidazole is used for treating Chagas disease (CD). This cross-sectional study aimed to characterize the adverse drug reactions (ADRs) of benznidazole at a public hospital in Brazil’s Federal District. METHODS: Medical records were analyzed and ADRs were categorized by...

Full description

Bibliographic Details
Main Authors:	Maria Katarine Costa Lucas Gontijo, Hilda Maria Benevides da Silva de Arruda, Elza Ferreira Noronha, Maria Inês de Toledo
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Medicina Tropical (SBMT) 2020-01-01
Series:	Revista da Sociedade Brasileira de Medicina Tropical
Subjects:	Chagas disease Benznidazole Drug-related side effects Adverse reactions
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822020000100622&tlng=en

Similar Items

Adverse systemic reaction to benznidazole
by: María Verónica Pacheco Coronel, et al.

Pharmacogenomic Profile and Adverse Drug Reactions in a Prospective Therapeutic Cohort of Chagas Disease Patients Treated with Benznidazole
by: Lucas A. M. Franco, et al.
Published: (2021-02-01)

Enfermedad de Chagas aguda, en un adulto tratado con benznidazol (Rochagan®) en Costa Rica
by: Víctor M. Montenegro, et al.
Published: (2004-06-01)

Enfermedad de Chagas aguda, en un adulto tratado con benznidazol (Rochagan®) en Costa Rica
by: Víctor M. Montenegro, et al.
Published: (2004-06-01)

Benznidazole vs benznidazole in multilamellar liposomes: how different they interact with blood components?
by: Maria Jose Morilla, et al.
Published: (2005-04-01)

Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole
by: Marisa Liliana Fernández, et al.
Published: (2016-03-01)

Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole
by: Cristina Vázquez, et al.
Published: (2023-01-01)

Uneventful benznidazole treatment of acute Chagas disease during pregnancy: a case report
by: Valeria Rita Corrêa, et al.
Published: (2014-06-01)

Response to different benznidazole doses in animal models of chronic phase Chagas disease: a critical review
by: Cauê Benito Scarim, et al.

Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease
by: Margoth Moreno, et al.
Published: (2010-11-01)

Parasitemia and antibody response to benznidazole treatment in a cohort of patients with chronic Chagas disease
by: Carlos Henrique Valente Moreira, et al.
Published: (2023-09-01)

Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: An experimental murine model of acute Chagas
by: Luis Eduardo Echeverría, et al.

Reações adversas em pacientes com doença de Chagas tratados com benzonidazol, no Estado do Ceará Adverse reactions in Chagas disease patients treated with benznidazole, in the State of Ceará
by: Vânia Maria Oliveira de Pontes, et al.
Published: (2010-04-01)

Mixed T Helper1/T Helper2/T Cytotoxic Profile in Subjects with Chronic Chagas Disease with Hypersensitivity Reactions to Benznidazole
by: Melisa D. Castro Eiro, et al.
Published: (2022-08-01)

Benznidazole levels in blood vary with age in rats
by: Romina Fernanda Bulffer, et al.
Published: (2011-05-01)

Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissão interrompida. I. Avaliação preliminar
by: José Rodrigues Coura, et al.
Published: (1997-04-01)

Evaluation of parasitemia by qPCR in patients with chronic Chagas disease treated with benznidazole
by: Bianca Sabaini Pavan Tycha, et al.
Published: (2023-01-01)

Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina
by: Leticia L Niborski, et al.
Published: (2016-06-01)

Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study
by: Alejandro M. Hasslocher-Moreno, et al.
Published: (2021-01-01)

Improving the solubility of the antichagasic drug benznidazole through formation of inclusion complexes with cyclodextrins
by: José Lamartine Soares Sobrinho, et al.
Published: (2011-09-01)

Benznidazole biotransformation in rat heart microsomal fraction without observable ultrastructural alterations: comparison to Nifurtimox-induced cardiac effects
by: María Montalto de Mecca, et al.
Published: (2008-09-01)

Benznidazole therapy for Chagas disease in asymptomatic Trypanosoma cruzi -seropositive former blood donors: evaluation of the efficacy of different treatment regimens
by: André Pires Antunes, et al.

Modulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas disease
by: María Cecilia Albareda, et al.
Published: (2015-05-01)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
by: Miriam Rolon, et al.
Published: (2022-08-01)

Poly-ε-Caprolactone Implants for Benznidazole Prolonged Release: An Alternative to Chagas Disease Oral Treatment
by: Ana Lia Mazzeti, et al.
Published: (2023-04-01)

Transcriptomic analysis of benznidazole-resistant and susceptible Trypanosoma cruzi populations
by: Davi Alvarenga Lima, et al.
Published: (2023-05-01)

High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala
by: Lucia Brum-Soares, et al.

Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial
by: Anis Rassi Jr, et al.

Treatment With Suboptimal Dose of Benznidazole Mitigates Immune Response Molecular Pathways in Mice With Chronic Chagas Cardiomyopathy
by: Priscila Silva Grijó Farani, et al.
Published: (2021-07-01)

A serological, parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention
by: Girley Francisco Machado-de-Assis, et al.
Published: (2013-11-01)

Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial
by: D. Molina-Morant, et al.
Published: (2020-04-01)

Evaluation of in vitro anti-Trypanosoma cruzi activity of medications benznidazole, amiodarone hydrochloride, and their combination
by: Angela Maria Lourenço, et al.

Benznidazole and amiodarone combined treatment attenuates cytoskeletal damage in Trypanosoma cruzi-infected cardiac cells
by: Juliana Magalhães Chaves Barbosa, et al.
Published: (2022-08-01)

Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection
by: Juliana Magalhães Chaves Barbosa, et al.
Published: (2022-02-01)

Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain
by: Edson L.P. Camandaroba, et al.
Published: (2003-04-01)

<b>Trypanocidal activity of genotoxic concentration of benznidazole on epimastigote forms of <i>Trypanosoma cruzi</i></b> - 10.4025/actascihealthsci.v34ispec.12337
by: Edilson Nobuyoshi Kaneshima, et al.
Published: (2012-10-01)

Caracterização físico-química do fármaco antichagásico benznidazol Physicochemical characterization of antichagasic benznidazole
by: Flávia Pires Maximiano, et al.
Published: (2010-01-01)

Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with <it>trypanosoma cruzi</it> antigens
by: Sathler-Avelar Renato, et al.
Published: (2012-05-01)

Clinical and serological evolution in chronic Chagas disease patients in a 4-year pharmacotherapy follow-up: a preliminary study
by: Monica Coelho Andrade, et al.
Published: (2013-12-01)

Miltefosine and Benznidazole Combination Improve Anti-Trypanosoma cruzi In Vitro and In Vivo Efficacy
by: Julián Ernesto Nicolás Gulin, et al.
Published: (2022-07-01)